CD274 and neoplasm: In this light, a recent phase 2 trial (NCT02207530) in recurrent/metastatic (R/M) HNSCC patients indicated that patients with ≥ 25% of tumor cells expressing PD-L1 exhibited favored responses to durvalumab therapy (10 mg/kg intravenously) [163].